PIRS - Pieris Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5223.65M
Enterprise Value 3162.13M
Trailing P/E N/A
Forward P/E 1-4.45
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)6.68
Price/Book (mrq)7.39
Enterprise Value/Revenue 34.84
Enterprise Value/EBITDA 6-4.95

Trading Information

Stock Price History

Beta (3Y Monthly) 0.86
52-Week Change 3-8.38%
S&P500 52-Week Change 32.36%
52 Week High 36.0400
52 Week Low 32.3900
50-Day Moving Average 34.8406
200-Day Moving Average 33.8404

Share Statistics

Avg Vol (3 month) 3529.23k
Avg Vol (10 day) 3466.34k
Shares Outstanding 549.26M
Float 45.01M
% Held by Insiders 10.23%
% Held by Institutions 172.84%
Shares Short (Jul 15, 2019) 41.94M
Short Ratio (Jul 15, 2019) 46.43
Short % of Float (Jul 15, 2019) 43.94%
Short % of Shares Outstanding (Jul 15, 2019) 43.93%
Shares Short (prior month Jun 14, 2019) 41.93M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 21/2
Last Split Date 3Dec 8, 2014

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin -84.75%
Operating Margin (ttm)-99.65%

Management Effectiveness

Return on Assets (ttm)-13.71%
Return on Equity (ttm)-70.22%

Income Statement

Revenue (ttm)33.49M
Revenue Per Share (ttm)0.63
Quarterly Revenue Growth (yoy)105.80%
Gross Profit (ttm)29.1M
EBITDA -32.78M
Net Income Avi to Common (ttm)-28.39M
Diluted EPS (ttm)-0.5330
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)110.78M
Total Cash Per Share (mrq)2.25
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)3.02
Book Value Per Share (mrq)0.61

Cash Flow Statement

Operating Cash Flow (ttm)-47.51M
Levered Free Cash Flow (ttm)-37.08M